DR info

臨床試験数 : 13 / 薬物数 : 16 - (DrugBank : 3) / 標的遺伝子数 : 1 - 標的パスウェイ数 : 6

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

BBP-671
   CoA Therapeutics, Inc., a BridgeBio company
      2021   Phase 1   NCT04836494   United States;
CX-016492
   ModernaTX, Inc
      2020   Phase 1;Phase 2   EUCTR2019-003529-36-GB   Canada;United Kingdom;United States;
CX-017950
   ModernaTX, Inc
      2020   Phase 1;Phase 2   EUCTR2019-003529-36-GB   Canada;United Kingdom;United States;
Carbaglu
   Mendel Tuchman
      2012   Phase 2   NCT01599286   United States;
Carglumic Acid (Carbaglu®)
   National Taiwan University Hospital
      2019   -   NCT04284917   Taiwan;
Disodium citrate
   Nicola Longo
      2008   Phase 1   NCT00645879   United States;
Glutamine
   Nicola Longo
      2008   Phase 1   NCT00645879   United States;
HST5040
   HemoShear Therapeutics
      2021   Phase 2   NCT04732429   United States;
MRNA-3927
   ModernaTX, Inc
      2020   Phase 1;Phase 2   EUCTR2019-003529-36-GB   Canada;United Kingdom;United States;
   ModernaTX, Inc.
      2021   Phase 1/Phase 2   NCT05130437   Canada;United Kingdom;United States;
      2021   Phase 1/Phase 2   NCT04159103   Canada;United Kingdom;United States;
Ornithine alpha ketoglutarate
   Nicola Longo
      2008   Phase 1   NCT00645879   United States;